An exploratory study of a product in Sienna Biopharmaceuticals’ Topical By Design platform showed modest results for psoriasis patients who used the therapy for 10 days. Subjects who applied the topical medication as part of the 15-person, double-blind study did not see a significant reduction in inflammation, but the test did show a “modulation” of…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
